Zurzuvae (Zuranolone) Patent Expiration, LOE Window & CMS Spending

Zurzuvae (Zuranolone) by Biogen: FDA Orange Book core substance LOE 2037-08-23, 0 AB generics, $24.9M 2024 CMS Part D & Medicaid spend, and $15,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiogen
FDA Application & PathwayN217369 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-08-23
Last Listed Patent or Exclusivity Date2037-08-23
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$24.9M
2024 Medicare Part D Spend$544K
2024 Medicaid Spend$24.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($15,900 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.